Canine Blood Pressure Management: ARBs and Cardiovascular Medications for Dogs Across the UK — Semintra, Telmisartan, Losartan and Proven Kidney Protection Strategies (2025)
Published on Thursday, 21 August 2025
Managing elevated blood pressure and chronic kidney disease in dogs requires careful consideration of pharmaceutical options, and angiotensin receptor blockers have emerged as a cornerstone therapy in contemporary veterinary practice. Unlike ACE inhibitors, ARBs work through a distinct mechanism to reduce systemic vascular resistance whilst protecting renal function and minimising proteinuria in dogs of all ages and sizes. UK veterinary practices increasingly advocate for ARB-based protocols when dogs present with resistant hypertension, progressive proteinuric nephropathy, or when previous ACE inhibitor therapy has proven inadequate. This comprehensive guide explores five evidence-based treatments that UK veterinarians recommend, including Semintra—the gold-standard licensed telmisartan formulation—alongside bespoke compounded preparations and complementary ACE inhibitor alternatives. Whether your dog requires immediate blood pressure intervention, long-term renal protection, or a tailored switch from conventional therapy, understanding the distinctions between these medications ensures informed decision-making in partnership with your veterinary team. We examine efficacy data, practical dosing considerations specific to the UK pharmaceutical landscape, palatability profiles that matter for daily administration, and the monitoring protocols your vet will employ to ensure optimal outcomes.
Top Picks Summary
Semintra (Telmisartan) Oral Solution for Cats
Semintra delivers telmisartan, a true ARB formulation in an oral solution that allows fine dose titration and practical off‑label use in dogs for targeted RAAS blockade to protect heart and kidneys. Its liquid format and direct AT1 receptor antagonism distinguish it from ACE inhibitor tablets on this list, offering a technical advantage in dosing precision and often a lower incidence of ACE‑inhibitor‑associated side effects; financially it can be more cost‑effective for weight‑based titration compared with multiple tablet products. As the only dedicated telmisartan product here, it is the primary ARB option veterinarians consider alongside ACE inhibitor and pimobendan regimens in the UK (2025).
These medications represent the most clinically robust options available through UK veterinary channels, combining demonstrated efficacy in controlling canine hypertension with favourable safety profiles when appropriately monitored. Each offers distinct advantages: licensed formulations provide pharmaceutical quality assurance, compounded preparations enable bespoke dosing, and the range ensures your vet can tailor therapy to your individual dog's requirements.
Understanding Angiotensin Receptor Blockers in Canine Medicine
Angiotensin receptor blockers function by selectively blocking AT1 receptors on vascular smooth muscle and renal tissue, preventing vasoconstriction and aldosterone release without inhibiting bradykinin metabolism—a key distinction from ACE inhibitors that occasionally causes adverse effects. In dogs with chronic kidney disease, ARBs reduce glomerular hyperfiltration and proteinuria through haemodynamic and anti-inflammatory mechanisms. British veterinary nephrology increasingly recognises ARBs as either first-line therapy or superior alternatives when ACE inhibitors have failed to achieve adequate blood pressure control or proteinuria reduction.
ARBs selectively block angiotensin II AT1 receptors, reducing blood pressure through different pathways than ACE inhibitors
Semintra is the only licensed veterinary ARB in the UK, providing pharmaceutical quality assurance and established dosing protocols
Compounded telmisartan and losartan preparations allow individualised dosing for dogs of varied weights and kidney function
ARBs demonstrate particular benefit in proteinuric kidney disease, often reducing urinary protein excretion more effectively than ACE inhibitors alone
Combination therapy with ACE inhibitors may provide synergistic renin-angiotensin system blockade in resistant cases
Blood pressure monitoring, baseline and periodic renal panels, and electrolyte assessments are essential during ARB therapy
Potential adverse effects include hyperkalaemia, azotaemia worsening, and hypotension—requiring veterinary oversight throughout treatment
ARBs are contraindicated in pregnant bitches and dogs with bilateral renal artery stenosis, though such conditions are rare in canine practice
Frequently Asked Questions
Which product is best for dog kidney proteinuria?
For dog kidney proteinuria with RAAS targeting, Semintra (Telmisartan) oral solution is the closest match, since it delivers telmisartan as a true ARB in a liquid once-daily format for accurate dose titration and veterinarian-prescribed proteinuria reduction; rating 4.5.
What dosing and receptor mechanism does Semintra use?
Semintra (Telmisartan) is a telmisartan oral solution designed for liquid, once-daily dosing that enables accurate titration, and it works via direct AT1 receptor antagonism; rating 4.5.
How does Cardalis pricing compare to simpler options?
No prices are provided for Cardalis or the other options on this page, so I can’t compare value. Cardalis is rated 4.2 and combines benazepril with spironolactone in chewable tablets for dual-action RAAS and aldosterone effects.
Is Fortekor licensed for both dogs and cats?
Yes—Fortekor (Benazepril) tablets are licensed for use in both dogs and cats with heart or renal disease. It’s an ACE inhibitor with once-daily dosing, available in multiple strengths; rating 4.4.
Conclusion
Selecting the right cardiovascular medication for your dog represents one of the most impactful health decisions you can make as a responsible owner. The five options detailed here—Semintra 10mg/mL Oral Solution, Telmisartan Compounded Oral Suspension, Losartan Compounded Tablets, Benazepril HCl Tablets, and Enalapril Maleate Tablets—reflect the spectrum of contemporary UK practice, from licensed proprietary formulations to individualised compounded therapies and established ACE inhibitor benchmarks. Semintra remains the preferred first-line choice when veterinary-labelled telmisartan is clinically appropriate and accessible; compounded alternatives provide flexibility for dogs requiring precise dose titration or those with specific palatability needs; whilst benazepril and enalapril continue to serve valuable roles in multimodal hypertension management. Your veterinary surgeon will weigh factors including your dog's specific diagnosis, concurrent medications, renal function markers, and tolerance profile to recommend the most suitable therapy. We encourage you to return with specific clinical questions or explore additional resources through our site, and always prioritise direct consultation with your veterinary team for treatment decisions bespoke to your dog's health needs.